National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey

被引：0

作者：

Dursun, A. ^{[1
]}

Bavbek, S. ^{[2
]}

Misirligil, Z. ^{[2
]}

Erdener, F. ^{[3
]}

Buyukozturk, S. ^{[4
]}

Aydin, O. ^{[2
]}

Gemicioglu, B. ^{[5
]}

Bayrak, P. ^{[6
]}

Erkekol, Oner F. ^{[1
]}

Yildirim, Z. ^{[7
]}

Cilli, A. ^{[8
]}

Boz, Bingol A. ^{[9
]}

Alpaydyn, Ozgen A. ^{[10
]}

Karakoc, G. ^{[11
]}

Gorguner, M. ^{[12
]}

Karakaya, G. ^{[13
]}

Isik, R. ^{[14
]}

Sapan, N. ^{[15
]}

Bakirtas, A. ^{[16
]}

机构：

[1] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Allergy Clin, Ankara, Turkey

[2] Ankara Univ, Sch Med, Dept Resp Med, Div Clin Immunol & Allergy, TR-06100 Ankara, Turkey

[3] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey

[4] Istanbul Univ, Istanbul Med Sch, Dept Internal Med, Div Allerg Dis, Istanbul, Turkey

[5] Istanbul Univ, Cerrahpasa Med Sch, Dept Resp Med, Istanbul, Turkey

[6] Celal Bayar Univ, Sch Med, Dept Internal Med, Div Clin Immunol & Allergy, Manisa, Turkey

[7] Fatih Univ, Sch Med, Dept Resp Med, Ankara, Turkey

[8] Akdeniz Univ, Sch Med, Dept Resp Med, TR-07058 Antalya, Turkey

[9] Akdeniz Univ, Sch Med, Dept Pediat, Div Allergy, TR-07058 Antalya, Turkey

[10] Celal Bayar Univ, Sch Med, Dept Resp Med, Manisa, Turkey

[11] Cukurova Univ, Sch Med, Dept Pediat, Div Allergy, Adana, Turkey

[12] Ataturk Univ, Sch Med, Dept Resp Med, Erzurum, Turkey

[13] Hacettepe Univ, Sch Med, Dept Resp Med, Adult Allergy Unit, Ankara, Turkey

[14] Seyhan Training & Res Hosp, Adult Allergy Unit, Adana, Turkey

[15] Uludag Univ, Sch Med, Dept Pediat, Div Allergy, Bursa, Turkey

[16] Gazi Univ, Sch Med, Dept Pediat, Div Allergy, Ankara, Turkey

来源：

ALLERGY | 2011年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1786

引用

页码：675 / 676

页数：2

共 50 条

[21] FDA post-marketing safety decisions
Klein, Donald F.
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (08) : 1305 - 1306
[22] Safety monitoring of ophthalmic biologics: analysis of pre and post-marketing safety data
Penedones, Ana
Batel-Marques, Francisco
PHARMACOTHERAPY, 2014, 34 (06): : E86 - E86
[23] Post-marketing device safety surveillance
Vidi, Venkatesan D.
Matheny, Michael E.
Resnic, Frederic S.
CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 307 - 308
[24] USE OF OMALIZUMAB IN FOUR-YEAR-OLD WITH SEVERE PERSISTENT ALLERGIC ASTHMA
Patel, G.
Pasha, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S93 - S93
[25] Efficacy And Safety Of Omalizumab In Japanese Patients With Persistent Allergic Severe Asthma Experience In Japan
Yatagai, Y.
Saito, T.
Fukai, S.
Sekine, A.
Miura, Y.
Hayashihara, K.
Tanaka, T.
Tsunoda, Y.
Miyazaki, K.
Lin, S.
Umetsu, Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[26] Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Stollenwerk, Ariane
Sohns, Melanie
Heisig, Fabian
Elling, Christian
von Zabern, Detlef
ADVANCES IN THERAPY, 2018, 35 (01) : 12 - 30
[27] Use of omalizumab in a severe asthma clinic
Gibson, Peter G.
Taramarcaz, Philip
Mcdonald, Vanessa M.
RESPIROLOGY, 2007, 12 : S35 - S44
[28] Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Ariane Stollenwerk
Melanie Sohns
Fabian Heisig
Christian Elling
Detlef von Zabern
Advances in Therapy, 2018, 35 : 12 - 30
[29] Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Mukherjee, Manali
Kjarsgaard, Melanie
Radford, Katherine
Huang, Chynna
Leigh, Richard
Dorscheid, Delbert R.
Lemiere, Catherine
Boulet, Louis-Philippe
Waserman, Susan
Martin, James
Nair, Parameswaran
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2019, 15 (1):
[30] Evaluating the efficacy of omalizumab in severe persistent asthma patients
Silveira, Antonio Miguel Ferrao
Carreto, Luis
Pardal, Cecilia
EUROPEAN RESPIRATORY JOURNAL, 2017, 50

← 1 2 3 4 5 →